Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
09 nov. 2023 16h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on November 8, 2023, the Company granted 18 new employees 141,800 restricted stock units (RSUs)...
Esperion Reports Third Quarter 2023 Financial Results
07 nov. 2023 06h00 HE
|
Esperion Therapeutics, Inc.
– Q3 U.S. Net Product Revenue Grew 45% Y/Y to $20.3 Million; Q3 Total Revenue Grew 79% Y/Y to $34.0 Million – – Q3 Retail Prescription Equivalents Grew 33% Y/Y and 8% Q/Q, Demonstrating Sustained...
Esperion to Participate in Jefferies London Healthcare Conference
31 oct. 2023 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the Jefferies London Healthcare Conference. Sheldon Koenig, President and Chief...
Esperion to Report Third Quarter 2023 Financial Results on November 7
24 oct. 2023 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report third quarter 2023 financial results before the market opens on Tuesday, November 7, 2023....
American College of Cardiology Program to Increase Cholesterol Screenings
12 sept. 2023 10h15 HE
|
Esperion Therapeutics, Inc.; The American College of Cardiology
Quality Improvement and Education Program sponsored by Amgen, Esperion to improve adherence to guideline recommendations for managing LDL WASHINGTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- The American...
Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference
28 août 2023 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference. Sheldon Koenig,...
Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023
26 août 2023 11h00 HE
|
Esperion Therapeutics, Inc.
– In total cardiovascular event analysis, bempedoic acid shows 20% risk reduction in MACE-4 and 17% risk reduction in MACE-3 – – In an analysis of patients with diabetes, bempedoic acid shows 17%...
Two CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023
11 août 2023 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced two oral presentations to take place in the Late-Breaking Science Session entitled “Clinical trial updates...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
08 août 2023 16h15 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on August 8, 2023, the Company granted five new employees 14,000 restricted stock units (RSUs) under...
Esperion Reports Second Quarter 2023 Financial Results
01 août 2023 06h00 HE
|
Esperion Therapeutics, Inc.
– Q2 U.S. Net Product Revenue Grew 49% Y/Y to $20.3 Million – – Q2 Retail Prescription Equivalents Grew 26% Y/Y; Q2 New to Brand Prescriptions Grew 28% Q/Q – – Submitted Applications for Expanded...